Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Betahistine dihydrochloride
All products: not a benefit
Auro-Betahistine · DIN 02449145 · 8 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Auro-Betahistine · DIN 02449145
Manufacturer: Auro Pharma Inc.; listing date 2016-02-25
Health Canada: Marketed since 2015-11-30 · brand AURO-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 8 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Betahistine: Formulary list price $0.21 per unit (the source does not state the unit; exact figure $0.2070). What the ministry pays, not the patient.
Ministry pays: $0.2070 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02449145)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02449145).
DIN 02449145: Auro-Betahistine
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 241200077; group id 362; item number 0846; lccId None; manufacturer id AUR
Source form: Tab; strength: 8mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2070; ministry $0.2070
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02449145
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93496
Interchangeable products
M-Betahistine · DIN 02519682 · $0.2259
Mint-Betahistine · DIN 02538121 · $0.2259
NRA-Betahistine · DIN 02544911 · $0.2259
Serc · DIN 02240601 · not recorded
Teva-Betahistine · DIN 02280183 · $0.2259
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02449145
Shortage record checked October 6, 2026
M-Betahistine · DIN 02519682 · 8 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Betahistine · DIN 02519682
Manufacturer: Mantra Pharma Inc.; listing date 2022-05-31
Health Canada: Marketed since 2022-07-27 · brand M-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 8 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordM-Betahistine: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2259). What the ministry pays, not the patient.
Ministry pays: $0.2259 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02519682)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02519682).
DIN 02519682: M-Betahistine
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 241200077; group id 362; item number 0846; lccId None; manufacturer id MAT
Source form: Tab; strength: 8mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2259; ministry $0.2259
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02519682
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100892
Interchangeable products
Auro-Betahistine · DIN 02449145 · $0.2070
Mint-Betahistine · DIN 02538121 · $0.2259
NRA-Betahistine · DIN 02544911 · $0.2259
Serc · DIN 02240601 · not recorded
Teva-Betahistine · DIN 02280183 · $0.2259
Shortage status: resolved shortage (ended February 4, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02519682
Shortage record checked October 6, 2026
Mint-Betahistine · DIN 02538121 · 8 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Betahistine · DIN 02538121
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-01-31
Health Canada: Marketed since 2023-10-20 · brand MINT-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 8 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Betahistine: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2259). What the ministry pays, not the patient.
Ministry pays: $0.2259 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02538121)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02538121).
DIN 02538121: Mint-Betahistine
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 241200077; group id 362; item number 0846; lccId None; manufacturer id MIN
Source form: Tab; strength: 8mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2259; ministry $0.2259
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02538121
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102687
Interchangeable products
Auro-Betahistine · DIN 02449145 · $0.2070
M-Betahistine · DIN 02519682 · $0.2259
NRA-Betahistine · DIN 02544911 · $0.2259
Serc · DIN 02240601 · not recorded
Teva-Betahistine · DIN 02280183 · $0.2259
Shortage status: resolved shortage (ended June 13, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02538121
Shortage record checked October 6, 2026
NRA-Betahistine · DIN 02544911 · 8 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Betahistine · DIN 02544911
Manufacturer: Nora Pharma; listing date 2024-08-30
Health Canada: Marketed since 2024-06-05 · brand NRA-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 8 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNRA-Betahistine: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2259). What the ministry pays, not the patient.
Ministry pays: $0.2259 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02544911)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02544911).
DIN 02544911: NRA-Betahistine
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 241200077; group id 362; item number 0846; lccId None; manufacturer id NRA
Source form: Tab; strength: 8mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2259; ministry $0.2259
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02544911
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103354
Interchangeable products
Auro-Betahistine · DIN 02449145 · $0.2070
M-Betahistine · DIN 02519682 · $0.2259
Mint-Betahistine · DIN 02538121 · $0.2259
Serc · DIN 02240601 · not recorded
Teva-Betahistine · DIN 02280183 · $0.2259
Shortage status: resolved shortage (ended March 24, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02544911
Shortage record checked October 6, 2026
Teva-Betahistine · DIN 02280183 · 8 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Betahistine · DIN 02280183
Manufacturer: Teva Canada Limited; listing date 2011-05-19
Health Canada: Marketed since 2014-01-09 · brand TEVA-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 8 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Betahistine: Formulary list price $0.23 per unit (the source does not state the unit; exact figure $0.2259). What the ministry pays, not the patient.
Ministry pays: $0.2259 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02280183)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02280183).
DIN 02280183: Teva-Betahistine
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 241200077; group id 362; item number 0846; lccId None; manufacturer id TEV
Source form: Tab; strength: 8mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.2259; ministry $0.2259
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02280183
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76586
Interchangeable products
Auro-Betahistine · DIN 02449145 · $0.2070
M-Betahistine · DIN 02519682 · $0.2259
Mint-Betahistine · DIN 02538121 · $0.2259
NRA-Betahistine · DIN 02544911 · $0.2259
Serc · DIN 02240601 · not recorded
Shortage status: discontinued (August 28, 2025, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02280183
Shortage record checked October 6, 2026
Auro-Betahistine · DIN 02449153 · 16 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Auro-Betahistine · DIN 02449153
Manufacturer: Auro Pharma Inc.; listing date 2016-02-25
Health Canada: Marketed since 2015-11-30 · brand AURO-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordAuro-Betahistine: Formulary list price $0.36 per unit (the source does not state the unit; exact figure $0.3557). What the ministry pays, not the patient.
Ministry pays: $0.3557 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02449153)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02449153).
DIN 02449153: Auro-Betahistine
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id AUR
Source form: Tab; strength: 16mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.3557; ministry $0.3557
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02449153
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93497
Interchangeable products
Betahistine · DIN 02466449 · $0.3557
Co Betahistine · DIN 02374757 · $0.3557
M-Betahistine · DIN 02519690 · $0.3557
Mint-Betahistine · DIN 02538148 · $0.3557
NRA-Betahistine · DIN 02544938 · $0.3557
PMS-Betahistine · DIN 02330210 · $0.3557
Serc · DIN 02243878 · not recorded
Teva-Betahistine · DIN 02280191 · $0.3557
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02449153
Shortage record checked October 6, 2026
M-Betahistine · DIN 02519690 · 16 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
M-Betahistine · DIN 02519690
Manufacturer: Mantra Pharma Inc.; listing date 2022-05-31
Health Canada: Marketed since 2022-07-25 · brand M-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordM-Betahistine: Formulary list price $0.36 per unit (the source does not state the unit; exact figure $0.3557). What the ministry pays, not the patient.
Ministry pays: $0.3557 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02519690)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02519690).
DIN 02519690: M-Betahistine
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id MAT
Source form: Tab; strength: 16mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.3557; ministry $0.3557
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02519690
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100893
Interchangeable products
Auro-Betahistine · DIN 02449153 · $0.3557
Betahistine · DIN 02466449 · $0.3557
Co Betahistine · DIN 02374757 · $0.3557
Mint-Betahistine · DIN 02538148 · $0.3557
NRA-Betahistine · DIN 02544938 · $0.3557
PMS-Betahistine · DIN 02330210 · $0.3557
Serc · DIN 02243878 · not recorded
Teva-Betahistine · DIN 02280191 · $0.3557
Shortage status: resolved shortage (ended February 4, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02519690
Shortage record checked October 6, 2026
Mint-Betahistine · DIN 02538148 · 16 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mint-Betahistine · DIN 02538148
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-01-31
Health Canada: Marketed since 2023-10-20 · brand MINT-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordMint-Betahistine: Formulary list price $0.36 per unit (the source does not state the unit; exact figure $0.3557). What the ministry pays, not the patient.
Ministry pays: $0.3557 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02538148)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02538148).
DIN 02538148: Mint-Betahistine
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id MIN
Source form: Tab; strength: 16mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.3557; ministry $0.3557
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02538148
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102688
Interchangeable products
Auro-Betahistine · DIN 02449153 · $0.3557
Betahistine · DIN 02466449 · $0.3557
Co Betahistine · DIN 02374757 · $0.3557
M-Betahistine · DIN 02519690 · $0.3557
NRA-Betahistine · DIN 02544938 · $0.3557
PMS-Betahistine · DIN 02330210 · $0.3557
Serc · DIN 02243878 · not recorded
Teva-Betahistine · DIN 02280191 · $0.3557
Shortage status: resolved shortage (ended June 13, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02538148
Shortage record checked October 6, 2026
NRA-Betahistine · DIN 02544938 · 16 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
NRA-Betahistine · DIN 02544938
Manufacturer: Nora Pharma; listing date 2024-08-30
Health Canada: Marketed since 2024-06-05 · brand NRA-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordNRA-Betahistine: Formulary list price $0.36 per unit (the source does not state the unit; exact figure $0.3557). What the ministry pays, not the patient.
Ministry pays: $0.3557 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02544938)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02544938).
DIN 02544938: NRA-Betahistine
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id NRA
Source form: Tab; strength: 16mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.3557; ministry $0.3557
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02544938
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103355
Interchangeable products
Auro-Betahistine · DIN 02449153 · $0.3557
Betahistine · DIN 02466449 · $0.3557
Co Betahistine · DIN 02374757 · $0.3557
M-Betahistine · DIN 02519690 · $0.3557
Mint-Betahistine · DIN 02538148 · $0.3557
PMS-Betahistine · DIN 02330210 · $0.3557
Serc · DIN 02243878 · not recorded
Teva-Betahistine · DIN 02280191 · $0.3557
Shortage status: resolved shortage (ended February 27, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02544938
Shortage record checked October 6, 2026
Serc · DIN 02243878 · 16 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Savings card: RxHelp ONE lists Serc (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Serc · DIN 02243878
Manufacturer: BGP Pharma ULC; listing date 2007-09-04
Health Canada: Marketed since 2016-09-07 · brand SERC · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Bgp pharma ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSerc: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02243878)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02243878).
DIN 02243878: Serc
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id BGP
Source form: Tab; strength: 16mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243878
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67819
Interchangeable products
Auro-Betahistine · DIN 02449153 · $0.3557
Betahistine · DIN 02466449 · $0.3557
Co Betahistine · DIN 02374757 · $0.3557
M-Betahistine · DIN 02519690 · $0.3557
Mint-Betahistine · DIN 02538148 · $0.3557
NRA-Betahistine · DIN 02544938 · $0.3557
PMS-Betahistine · DIN 02330210 · $0.3557
Teva-Betahistine · DIN 02280191 · $0.3557
Shortage status: avoided shortage; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02243878
Shortage record checked October 6, 2026
Teva-Betahistine · DIN 02280191 · 16 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Betahistine · DIN 02280191
Manufacturer: Teva Canada Limited; listing date 2007-09-04
Health Canada: Marketed since 2014-01-09 · brand TEVA-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordTeva-Betahistine: Formulary list price $0.36 per unit (the source does not state the unit; exact figure $0.3557). What the ministry pays, not the patient.
Ministry pays: $0.3557 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02280191)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02280191).
DIN 02280191: Teva-Betahistine
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id TEV
Source form: Tab; strength: 16mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.3557; ministry $0.3557
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02280191
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76587
Interchangeable products
Auro-Betahistine · DIN 02449153 · $0.3557
Betahistine · DIN 02466449 · $0.3557
Co Betahistine · DIN 02374757 · $0.3557
M-Betahistine · DIN 02519690 · $0.3557
Mint-Betahistine · DIN 02538148 · $0.3557
NRA-Betahistine · DIN 02544938 · $0.3557
PMS-Betahistine · DIN 02330210 · $0.3557
Serc · DIN 02243878 · not recorded
Shortage status: discontinued (August 28, 2025, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02280191
Shortage record checked October 6, 2026
Auro-Betahistine · DIN 02449161 · 24 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Auro-Betahistine · DIN 02449161
Manufacturer: Auro Pharma Inc.; listing date 2016-02-25
Health Canada: Marketed since 2015-11-30 · brand AURO-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Auro pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02449161)
Source record
DIN 02449161: Auro-Betahistine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id AUR
Source form: Tab; strength: 24mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4983; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02449161
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93498
Interchangeable products
Betahistine · DIN 02466457 · not recorded
Co Betahistine · DIN 02374765 · not recorded
M-Betahistine · DIN 02519704 · not recorded
Mint-Betahistine · DIN 02538156 · not recorded
NRA-Betahistine · DIN 02544946 · not recorded
PMS-Betahistine · DIN 02330237 · not recorded
Serc · DIN 02247998 · not recorded
Teva-Betahistine · DIN 02280205 · not recorded
Shortage status: resolved shortage (ended May 15, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02449161
Shortage record checked October 6, 2026
M-Betahistine · DIN 02519704 · 24 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
M-Betahistine · DIN 02519704
Manufacturer: Mantra Pharma Inc.; listing date 2022-05-31
Health Canada: Marketed since 2022-07-25 · brand M-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Mantra pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02519704)
Source record
DIN 02519704: M-Betahistine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id MAT
Source form: Tab; strength: 24mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4983; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02519704
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=100894
Interchangeable products
Auro-Betahistine · DIN 02449161 · not recorded
Betahistine · DIN 02466457 · not recorded
Co Betahistine · DIN 02374765 · not recorded
Mint-Betahistine · DIN 02538156 · not recorded
NRA-Betahistine · DIN 02544946 · not recorded
PMS-Betahistine · DIN 02330237 · not recorded
Serc · DIN 02247998 · not recorded
Teva-Betahistine · DIN 02280205 · not recorded
Shortage status: resolved shortage (ended February 4, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02519704
Shortage record checked October 6, 2026
Mint-Betahistine · DIN 02538156 · 24 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Mint-Betahistine · DIN 02538156
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2024-01-31
Health Canada: Marketed since 2023-10-31 · brand MINT-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Mint pharmaceuticals inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02538156)
Source record
DIN 02538156: Mint-Betahistine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id MIN
Source form: Tab; strength: 24mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4983; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02538156
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102689
Interchangeable products
Auro-Betahistine · DIN 02449161 · not recorded
Betahistine · DIN 02466457 · not recorded
Co Betahistine · DIN 02374765 · not recorded
M-Betahistine · DIN 02519704 · not recorded
NRA-Betahistine · DIN 02544946 · not recorded
PMS-Betahistine · DIN 02330237 · not recorded
Serc · DIN 02247998 · not recorded
Teva-Betahistine · DIN 02280205 · not recorded
Shortage status: resolved shortage (ended June 13, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02538156
Shortage record checked October 6, 2026
NRA-Betahistine · DIN 02544946 · 24 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
NRA-Betahistine · DIN 02544946
Manufacturer: Nora Pharma; listing date 2024-08-30
Health Canada: Marketed since 2024-06-05 · brand NRA-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Nora pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02544946)
Source record
DIN 02544946: NRA-Betahistine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id NRA
Source form: Tab; strength: 24mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4983; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02544946
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103356
Interchangeable products
Auro-Betahistine · DIN 02449161 · not recorded
Betahistine · DIN 02466457 · not recorded
Co Betahistine · DIN 02374765 · not recorded
M-Betahistine · DIN 02519704 · not recorded
Mint-Betahistine · DIN 02538156 · not recorded
PMS-Betahistine · DIN 02330237 · not recorded
Serc · DIN 02247998 · not recorded
Teva-Betahistine · DIN 02280205 · not recorded
Shortage status: resolved shortage (ended March 24, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02544946
Shortage record checked October 6, 2026
Serc · DIN 02247998 · 24 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Savings card: RxHelp ONE lists Serc (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Serc · DIN 02247998
Manufacturer: BGP Pharma ULC; listing date 2007-09-04
Health Canada: Marketed since 2016-06-20 · brand SERC · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Bgp pharma ulc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSerc: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02247998)
Source record
DIN 02247998: Serc
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id BGP
Source form: Tab; strength: 24mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02247998
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72312
Interchangeable products
Auro-Betahistine · DIN 02449161 · not recorded
Betahistine · DIN 02466457 · not recorded
Co Betahistine · DIN 02374765 · not recorded
M-Betahistine · DIN 02519704 · not recorded
Mint-Betahistine · DIN 02538156 · not recorded
NRA-Betahistine · DIN 02544946 · not recorded
PMS-Betahistine · DIN 02330237 · not recorded
Teva-Betahistine · DIN 02280205 · not recorded
Shortage status: resolved shortage (ended April 14, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02247998
Shortage record checked October 6, 2026
Teva-Betahistine · DIN 02280205 · 24 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked November 19, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Teva-Betahistine · DIN 02280205
Manufacturer: Teva Canada Limited; listing date 2007-09-04
Health Canada: Marketed since 2014-01-09 · brand TEVA-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02280205)
Source record
DIN 02280205: Teva-Betahistine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id TEV
Source form: Tab; strength: 24mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4983; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02280205
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76588
Interchangeable products
Auro-Betahistine · DIN 02449161 · not recorded
Betahistine · DIN 02466457 · not recorded
Co Betahistine · DIN 02374765 · not recorded
M-Betahistine · DIN 02519704 · not recorded
Mint-Betahistine · DIN 02538156 · not recorded
NRA-Betahistine · DIN 02544946 · not recorded
PMS-Betahistine · DIN 02330237 · not recorded
Serc · DIN 02247998 · not recorded
Shortage status: discontinued (August 28, 2025, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02280205
Shortage record checked October 6, 2026
Betahistine · DIN 02466449 · 16 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitDormant since July 23, 2026 · checked October 5, 2026 · What does dormant mean? StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Betahistine · DIN 02466449
Manufacturer: Sanis Health Inc.; listing date 2020-06-30
Health Canada: Dormant since 2026-07-23 · brand BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordBetahistine: Formulary list price $0.36 per unit (the source does not state the unit; exact figure $0.3557). What the ministry pays, not the patient.
Ministry pays: $0.3557 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02466449)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02466449).
DIN 02466449: Betahistine
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id SAI
Source form: Tab; strength: 16mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.3557; ministry $0.3557
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02466449
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95480
Interchangeable products
Auro-Betahistine · DIN 02449153 · $0.3557
Co Betahistine · DIN 02374757 · $0.3557
M-Betahistine · DIN 02519690 · $0.3557
Mint-Betahistine · DIN 02538148 · $0.3557
NRA-Betahistine · DIN 02544938 · $0.3557
PMS-Betahistine · DIN 02330210 · $0.3557
Serc · DIN 02243878 · not recorded
Teva-Betahistine · DIN 02280191 · $0.3557
Shortage status: active shortage (reported November 5, 2024, last updated November 12, 2024) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02466449
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 23, 2026 — choose a marketed DIN from the same-category list.
PMS-Betahistine · DIN 02330210 · 16 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitDormant since July 31, 2025 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Betahistine · DIN 02330210
Manufacturer: Pharmascience Inc.; listing date 2014-04-30
Health Canada: Dormant since 2025-07-31 · brand PMS-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordPMS-Betahistine: Formulary list price $0.36 per unit (the source does not state the unit; exact figure $0.3557). What the ministry pays, not the patient.
Ministry pays: $0.3557 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02330210)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02330210).
DIN 02330210: PMS-Betahistine
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id PMS
Source form: Tab; strength: 16mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.3557; ministry $0.3557
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02330210
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81597
Interchangeable products
Auro-Betahistine · DIN 02449153 · $0.3557
Betahistine · DIN 02466449 · $0.3557
Co Betahistine · DIN 02374757 · $0.3557
M-Betahistine · DIN 02519690 · $0.3557
Mint-Betahistine · DIN 02538148 · $0.3557
NRA-Betahistine · DIN 02544938 · $0.3557
Serc · DIN 02243878 · not recorded
Teva-Betahistine · DIN 02280191 · $0.3557
Shortage status: active shortage (reported not recorded, estimated to end January 1, 2027, last updated May 13, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02330210
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 31, 2025 — choose a marketed DIN from the same-category list.
Betahistine · DIN 02466457 · 24 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitDormant since July 23, 2026 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Betahistine · DIN 02466457
Manufacturer: Sanis Health Inc.; listing date 2020-06-30
Health Canada: Dormant since 2026-07-23 · brand BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Sanis health inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02466457)
Source record
DIN 02466457: Betahistine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id SAI
Source form: Tab; strength: 24mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4983; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02466457
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95481
Interchangeable products
Auro-Betahistine · DIN 02449161 · not recorded
Co Betahistine · DIN 02374765 · not recorded
M-Betahistine · DIN 02519704 · not recorded
Mint-Betahistine · DIN 02538156 · not recorded
NRA-Betahistine · DIN 02544946 · not recorded
PMS-Betahistine · DIN 02330237 · not recorded
Serc · DIN 02247998 · not recorded
Teva-Betahistine · DIN 02280205 · not recorded
Shortage status: active shortage (reported December 3, 2024, last updated December 4, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02466457
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 23, 2026 — choose a marketed DIN from the same-category list.
PMS-Betahistine · DIN 02330237 · 24 mg · tablet
Off-Formulary Interchangeable, not an ODB benefitDormant since July 31, 2025 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
PMS-Betahistine · DIN 02330237
Manufacturer: Pharmascience Inc.; listing date 2014-04-30
Health Canada: Dormant since 2025-07-31 · brand PMS-BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Pharmascience inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02330237)
Source record
DIN 02330237: PMS-Betahistine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id PMS
Source form: Tab; strength: 24mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4983; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02330237
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81599
Interchangeable products
Auro-Betahistine · DIN 02449161 · not recorded
Betahistine · DIN 02466457 · not recorded
Co Betahistine · DIN 02374765 · not recorded
M-Betahistine · DIN 02519704 · not recorded
Mint-Betahistine · DIN 02538156 · not recorded
NRA-Betahistine · DIN 02544946 · not recorded
Serc · DIN 02247998 · not recorded
Teva-Betahistine · DIN 02280205 · not recorded
Shortage status: active shortage (reported not recorded, estimated to end January 1, 2027, last updated May 13, 2025); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02330237
Shortage record checked October 6, 2026
Health Canada lists this DIN as Dormant since July 31, 2025 — choose a marketed DIN from the same-category list.
Serc · DIN 02240601 · 8 mg · tablet
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2005-02-07 — choose a marketed DIN from the same-category list.Discontinued February 7, 2005 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2005-02-07 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2005-02-07 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)Savings card: RxHelp ONE lists Serc (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim.
(rxhelp.ca ↗)1 brand, same coverage
Serc · DIN 02240601
Manufacturer: Solvay Pharma Inc.; listing date 2011-05-19
Health Canada: Cancelled post market since 2005-02-07 · brand SERC 8 MG · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 8 MG/TAB · company Solvay pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordSerc: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02240601)
Source record
DIN 02240601: Serc
Raw flags: sec3=Y, sec3b=Y
Item: 241200077; group id 362; item number 0846; lccId None; manufacturer id SPH
Source form: Tab; strength: 8mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02240601
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=64172
Interchangeable products
Auro-Betahistine · DIN 02449145 · $0.2070
M-Betahistine · DIN 02519682 · $0.2259
Mint-Betahistine · DIN 02538121 · $0.2259
NRA-Betahistine · DIN 02544911 · $0.2259
Teva-Betahistine · DIN 02280183 · $0.2259
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02240601
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since February 7, 2005 — choose a marketed DIN from the same-category list.
Co Betahistine · DIN 02374757 · 16 mg · tablet
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.Discontinued June 12, 2018 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; this DIN is on the ministry's EAP drug list (August 2026): submit an Exceptional Access request through SADIE with the clinical rationale; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Co Betahistine · DIN 02374757
Manufacturer: Cobalt Pharmaceuticals Company; listing date 2012-01-19
Health Canada: Cancelled post market since 2018-06-12 · brand ACT BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 16 MG · company Actavis pharma company · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordCo Betahistine: Formulary list price $0.36 per unit (the source does not state the unit; exact figure $0.3557). What the ministry pays, not the patient.
Ministry pays: $0.3557 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02374757)
Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02374757).
DIN 02374757: Co Betahistine
Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y
Item: 241200080; group id 362; item number 0847; lccId None; manufacturer id COB
Source form: Tab; strength: 16mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed)
Source prices (unrounded): $0.3557; ministry $0.3557
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02374757
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86007
Interchangeable products
Auro-Betahistine · DIN 02449153 · $0.3557
Betahistine · DIN 02466449 · $0.3557
M-Betahistine · DIN 02519690 · $0.3557
Mint-Betahistine · DIN 02538148 · $0.3557
NRA-Betahistine · DIN 02544938 · $0.3557
PMS-Betahistine · DIN 02330210 · $0.3557
Serc · DIN 02243878 · not recorded
Teva-Betahistine · DIN 02280191 · $0.3557
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02374757
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 12, 2018 — choose a marketed DIN from the same-category list.
Co Betahistine · DIN 02374765 · 24 mg · tablet
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.Discontinued June 12, 2018 · checked October 5, 2026
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.
Write on scriptnot an ODB benefit; the ministry's EAP drug list (August 2026) names this generic but not this DIN: confirm the product with the pharmacy or ministry before an Exceptional Access request; no criteria matched in the held records; confirm the applicable criteria through SADIE or the ministry; Health Canada lists this DIN as Cancelled post market since 2018-06-12 — choose a marketed DIN from the same-category list.
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
1 brand, same coverage
Co Betahistine · DIN 02374765
Manufacturer: Cobalt Pharmaceuticals Company; listing date 2012-01-19
Health Canada: Cancelled post market since 2018-06-12 · brand ACT BETAHISTINE · ATC N07CA01 BETAHISTINE · form Tablet · route Oral · ingredients BETAHISTINE HYDROCHLORIDE 24 MG · company Actavis pharma company · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product recordFormulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02374765)
Source record
DIN 02374765: Co Betahistine
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 241200087; group id 362; item number 0848; lccId None; manufacturer id COB
Source form: Tab; strength: 24mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $0.4983; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02374765
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86008
Interchangeable products
Auro-Betahistine · DIN 02449161 · not recorded
Betahistine · DIN 02466457 · not recorded
M-Betahistine · DIN 02519704 · not recorded
Mint-Betahistine · DIN 02538156 · not recorded
NRA-Betahistine · DIN 02544946 · not recorded
PMS-Betahistine · DIN 02330237 · not recorded
Serc · DIN 02247998 · not recorded
Teva-Betahistine · DIN 02280205 · not recorded
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02374765
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since June 12, 2018 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (24:12 Vasodilating Drugs) and how they are covered
Matched class: 24:12 Vasodilating Drugs
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Some products covered without a code (check the product listing): ISOSORBIDE DINITRATE, NITROGLYCERIN
24:12 Vasodilating Drugs
· 6 products · General benefit (3), Listed, not a benefit (3) · strengths: 5mg, 10mg, 30mg · SL Tab, Tab
· 20 products · General benefit (13), Temporary benefit (2), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4) · strengths: 0.4mg/Hr/20 Sq Cm, 0.6mg/Hr/30 Sq Cm, 0.4mg/Hr/14 Sq Cm, 0.6mg/Hr/21 Sq Cm, 0.3mg, 0.6mg, 0.4mg/Metered Dose, 0.2mg/Hr, 0.4mg/Hr, 0.6mg/Hr, 0.8mg/Hr · Patch, SL Tab, Sp-180 Dose Pk, Sp-75 Dose Pk, Spray-200 Dose Pk, Transdermal Patch
· 2 products · Listed, not a benefit (1),
Limited Use, codes 349 (1) · strengths: 200mg/25mg · Cap
· 1 products ·
Limited Use, codes 42, 43 · strengths: 30mg · Tab
· 3 products ·
Limited Use, codes 685 · strengths: 2.5mg, 5mg, 10mg · Tab
· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 5mg, 10mg · Tab
· 14 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 62.5mg, 125mg · Tab
· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 25mg, 50mg, 75mg · Tab
· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 60mg · ER Tab
· 10 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 0.5mg, 1.5mg, 1mg, 2.5mg, 2mg · Tab
· 73 products · Off-Formulary Interchangeable, not an ODB benefit (72), Off-Formulary Interchangeable, not an ODB benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 2.5mg, 5mg, 10mg, 20mg · Tab
· 16 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg, 5mg, 20mg · Orally Disintergrating Tab, Tab
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:12
Full class listing
Related classes: 24:04 Cardiac Drugs, 24:06 Antilipemic Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:32 Renin-Angiotensin Aldosterone Inhibitors
Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Availability
Teva-Betahistine · DIN 02280183
Shortage status: discontinued (2025-08-28, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02280183
Check this DIN againTeva-Betahistine · DIN 02280191
Shortage status: discontinued (2025-08-28, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02280191
Check this DIN againTeva-Betahistine · DIN 02280205
Shortage status: discontinued (2025-08-28, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02280205
Check this DIN againBetahistine · DIN 02466449
Shortage status: active shortage (reported 2024-11-05, last updated 2024-11-12) — report may be stale, confirm; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02466449
Check this DIN againPMS-Betahistine · DIN 02330210
Shortage status: active shortage (reported not recorded, estimated to end 2027-01-01, last updated 2025-05-13); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02330210
Check this DIN againBetahistine · DIN 02466457
Shortage status: active shortage (reported 2024-12-03, last updated 2024-12-04); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02466457
Check this DIN againPMS-Betahistine · DIN 02330237
Shortage status: active shortage (reported not recorded, estimated to end 2027-01-01, last updated 2025-05-13); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02330237
Check this DIN again